The introduction of highly active antiretroviral therapy (HAART), with either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor in combination with two or more nucleoside reverse transcriptase inhibitors, was a landmark event in the history of HIV treatment. Since 1996, HAART has been widely adopted in the USA and Western Europe, with profound impact on HIV-related morbidity and mortality 1±6 . In April 2001, ®fteen antiretroviral drugs had been licensed for use in Europe and the USA and an additional eight were in development. In Europe, the USA and Canada, the mortality of AIDS (Figure 1 ) and the incidence of different AIDS-de®ning illnesses ( Figure 2 ) have declined over the past decade. In the UK, new AIDS diagnoses dropped from 1187 in 1994 to 507 in 1999, the decline being steepest between 1996 and 1998 (from 941 to 522) and greatest in those infected through sex with men 1 . The biggest percentage reductions in incidence of AIDS diagnoses occurred with Pneumocystis carinii pneumonia (PCP) (35± 80%), Kaposi's sarcoma (34±75%), cryptosporidiosis (60± 88%), oesophageal candidiasis (29±81%) and cytomegalovirus (CMV) (70%) 2±6 , and discontinuation of primary and even secondary prophylaxis has proved possible for several of these infections 7 . The use of HAART has also been associated with remission of Kaposi's sarcoma, refractory cryptosporidiosis, and progressive multifocal leukoencephalopathy, in addition to improvement in many of the common HIV-related symptoms such as night sweats, fatigue, weight loss, and seborrhoeic dermatitis. Some unusual manifestations of infections have been reported as a result of the heightened immune response or immune reconstitution associated with antiretroviral therapy. These include lymphadenitis due to Mycobacterium avium complex, vitritis associated with CMV,¯are-up of hepatitis due to hepatitis B, and an aggressive course of multicentric Castleman's disease associated with human herpesvirus-8.
The spectrum of paediatric HIV disease has also changed dramaticallyÐnot only because of the availability of HAART but also because of prompt early diagnosis and treatment and the development of more reliable surrogate markers of disease progression. In addition, because of a widespread increase in screening of pregnant women for HIV, more patients are identi®ed as HIV-infected and receive antiretroviral therapy during pregnancy. This in turn has resulted in a sharp decline in the prevalence of childhood infection in developed countries. Since 1994 in various parts of Western Europe, mother-to-child HIV transmission rates have decreased from 25% to less than 8%.
CHALLENGES IN THE MANAGEMENT OF HIV DISEASE

Treatment failure
Despite the successes of antiretroviral treatment new diagnoses of HIV infection have not decreased, so the number of patients living with HIV continues to grow. In addition, it is becoming evident that sustained viral suppression with HAART may not be feasible in all patients receiving HAART. Several studies have found that 40±50% of patients experience virological failure within 12 to 24 months of starting HAART 8, 9 . Contributory factors include poor adherence to treatment because of high pill burdens and dietary restrictions, unacceptable side-effects, drug interactions resulting in suboptimal drug levels, and preexisting drug resistance. Although viral rebound does not seem often to cause clinical progression of disease, the longterm outlook for these patients is uncertain.
Toxicities
About 40% of patients develop one or more adverse reactions within 18 months of starting protease inhibitors, and side-effects speci®c to nucleoside and non-nucleoside reverse transcriptase inhibitors have also been recognized. The spectrum, overall, includes gastrointestinal problems, metabolic effects (hyperlipidaemia, hyperglycaemia, lactic acidosis, osteopenia), lipodystrophy or fat redistribution syndrome, hepatic dysfunction, peripheral neuropathy and renal toxicities 10 .
Peripheral neuropathy, which affects 10±35% of HIVinfected patients and 11±55% of those using didanosine (ddI), dideoxycytidine (ddC), lamivudine or stavudine, has emerged as one of the most dif®cult HIV-related symptoms or drug side-effects to manage. Neuropathy can greatly impair quality of life, particularly in patients without any remaining antiretroviral treatment options and in whom the neuropathy has progressed.
Role of palliative care in HIV
Although HIV has been transformed by HAART into a chronic rather than a uniformly fatal illness, palliative care continues to have an important evolving role. Increasingly, the WHO palliative care de®nition`active total care' includes use of antiretroviral therapy along with prevention or management of opportunistic infections, and the palliative approach of offering symptomatic and supportive care is seen as important at all stages of HIV disease 13±15 .
PALLIATIVE CARE ISSUES SPECIFIC TO HIV INFECTION
Common symptoms encountered in advanced HIV disease are summarized in Table 1 in patients with metastatic disease or degenerative neurological conditions, but several are speci®c to HIV disease.
Polypharmacy: chronic antiretroviral therapy and continued prophylaxis
Long-term virological control with HAART requires a high level of adherence. Experience from other chronic diseases, such as diabetes and hypertension indicates that patients who feel well ®nd it extraordinarily dif®cult to take their medications. In many HIV clinics, 20% of patients do not comply with therapy at all, and the remaining 80% probably comply only 60% of the time. Paterson and colleagues found that, even among patients with 90±95% adherence, the failure rate was 32% at three months, and of patients with 80±90% adherence about half experienced virological failure 12 . Since 95% adherence is a near impossible goal for many patients, there is a great need for more potent and simpli®ed regimens, with compact easy-to-swallow tablets or capsules, that are well tolerated and forgiving of occasional non-compliance. Polypharmacy for patients with advanced HIV disease is common. Many medications may be continued for reasons that are not clear, and hospice admission can offer an opportunity to rede®ne the goals of care and address the main symptoms. Here is an example:
A man aged 52 with advanced HIV disease and a recent history of PCP, CMV retinitis, wasting and chronic diarrhoea was transferred for hospice care from the hospital HIV inpatient unit after admission for low-grade fever and general debility. No underlying infection had been found but antibiotics had been started empirically. On leaving hospital he was taking, daily, the following: amoxycillin 500 mg63; erythromycin 500 mg64; co-trimoxazole 480 mg61;¯uconazole 50 mg61; multivitamins61; acyclovir 200 mg63; megestrol 80 mg63; prochlorperazine 10 mg 6 hourly as required; sustained-release morphine 60 mg64; immediate-release
V o l u m e 9 4 S e p t e m b e r 2 0 0 1 He was having dif®culty with oral intake. Since fatigue, anorexia, pain and anxiety were the main symptoms, after careful discussion with the patient and his HIV physician only the following medications were continued: co-trimoxazole 480 mg for PCP prophylaxis; acyclovir 400 mg62 for suppression of herpes; sustained-release morphine 60 mg62; immediate-release morphine 10 mg as required; senna 2 tablets at bedtime; lorazepam 1 mg as required.
Multiple medical problems and coexisting diagnoses
A substantial proportion of persons with HIV have other disorders such as asthma, diabetes, tuberculosis and hepatitis B or C that can complicate their management. Patients who become infected through injection drug use are particularly likely to be infected with hepatitis B and C infection, and HIV co-infection is a strong risk factor for progression to end-stage liver disease. Treatment of both these viral infections is also associated with greater risk of adverse events, and management of co-infection poses challenges for palliative care. In addition, such patients are likely to have limited support networks, to be estranged from their families and not to be accessing healthcare.
A woman of 29 had been a windsur®ng instructor abroad for many years. She had never injected drugs or had a blood transfusion. In May 1995 she was diagnosed HIV-1 positive; CD4 cell count 100610 6 /L, oral candida.
Phase 1
April 1996ÐAntiretroviral therapy with zidovudine and ddc May 1996ÐNausea and poor adherence. Antiretroviral therapy discontinued June 1996ÐRight-sided weakness and incontinence; magnetic resonance scan (MRI) consistent with progressive multifocal leucoencephalopathy (PML) June 1997ÐGeneralized seizures; progression of white matter lesions on MRI July 1997ÐGeneric hospice for terminal care; depressed, agitated, expressing wish to die Phase 2 August 1997ÐAdmitted to Mildmay Hospital brain impairment unit; regular eating and sleeping routine established; able to comply with PCP prophylaxis December 1997ÐReferred to start HAART; progresses from directly observed therapy to supervised dosette-based therapy to independent self-medication December 1998ÐDischarged to live independently; selfcaring, hygienic, smartly dressed, keeping appointments December 2000ÐWell at home, taking HAART.
Fluctuation in conditionÐdif®culty in identifying terminal phase
In cancer, the transition from active management to palliative care was originally thought to be a clearly de®ned cut-off, but in reality there is a gradual progression 12, 13 . With HIV disease the pattern is neither a sharply de®ned cut-off nor a gradual progression, but may be characterized by episodes requiring a considerable degree of symptom control, alternating with periods where little or none is required (Figure 3) . At times, combination antiretroviral therapy is the most effective management of HIV-related symptoms.
A 31-year-old woman from Francophone west Africa with limited English was an illegal immigrant living in the house of friends in London. She had no family in the UK, but was an active member of the local church.
She initially indicated that she had a child with her, but subsequently denied this. She remained adamant that no one should be informed of her diagnosis. Patients can be restored to independence and a good quality of life even after being considered terminal by their HIV specialist, nurses, and family 14, 15 . However, the unpredictable response to therapy in the setting of advanced HIV disease means that determining prognosis is often dif®cult. This may lead to the apparent paradox whereby the patient receives simultaneous active treatment for one HIV-related condition and palliation for another. For example, acute opportunistic infections, superimposed on a chronic debilitated state, may require short-term aggressive interventions even though the overall goal may be one of palliation. This up-and-down course represents a constant challenge to healthcare staff and family.
Increased risk of drug reactions and drug interactions
The expanding number of approved drugs to treat HIV infection increases options for patients but also presents challenges for the HIV physician. Since many of these drugs are substrates for cytochrome P450 drug-metabolizing enzymes in the liver, and since some of them are inhibitors or inducers of these enzymes, physicians need to be aware of the potential for pharmacokinetic drug interactions. Some undesirable drug interactions, such as those produced by rifabutin (used in the treatment of mycobacterial infection) and protease inhibitors, may be circumvented by modifying the dose of one or both drugs. P450 inducers such as efavirenz, nevirapine and nel®navir can reduce methadone concentrations, so HIV-infected patients taking methadone who are started on antiretroviral therapy should be monitored carefully and may require an increase in methadone dose. Finally patients should be cautioned that complementary medicines can interact with prescription drugs. St John's wort, a p450 enzyme inducer, substantially reduces indinavir concentrations and should be avoided by patients on antiretroviral therapy.
Isolation, stigma and lack of social support
In the past 5 years in the UK, there has been a pronounced rise in the number of new HIV infections in persons from West, South and East Africa (Figure 4) ; in South London, 40±50% of our patients are from sub-Saharan Africa. Patients from these communities tend not to have the HIV-1 infection diagnosed until they are symptomatic and already have advanced disease 16 . A reluctance to come forward for HIV testing is explained partly by lack of knowledge about the bene®ts of therapy but also by the continuing stigma associated with HIV in many of these communities, such that patients even after diagnosis may avoid disclosing their infection to anyone else. The stigma can result in reduced uptake of services that are identi®ably HIV-related (such as HIV hospices and wards). Continuing reassurance about con®dentiality is therefore important. Uncertain immigration status can also cause great anxiety and prevent family members from entering the UK to visit or care for their dying relative. The situation for asylum-seekers with HIV is particularly dif®cult. Unwillingness to inform an unsympathetic of®cial about their HIV status may mean that the patient is transferred outside London in accordance with the Immigration and Asylum Act, 1999. As an example, a recent resident at the Mildmay Hospital who was also an asylum-seeker was transferred from London to Bournemouth and then on to Hastings. On each occasion, links established with HIV professionals and cultural groups were disrupted, and the patient was relocated far from family and friends from the same ethnic group.
ORGANIZATION AND DELIVERY OF HIV PALLIATIVE CARE
In the UK, most people who are infected with HIV obtain their care from specialist hospital clinics. These clinics usually provide access to antiretroviral drugs as well as specialized services such as walk-in and day-care facilities, counselling, complementary treatments, peer support and advice about services and bene®ts.
Hospital
Patient surveys in the past have shown that less than 10% of HIV-infected patients who expressed a preference wished to die in hospital 17 dying in hospital, largely because dying in hospital is usually a fait accompli rather than an active decision. Drawbacks of hospitals include the variable quality of palliative care in acute medical settings and the focus on management of acute problems in a person who may be slowly dying.
Hospice
Another environment for palliative care is a residential hospice. Many district hospitals and community areas in the UK provide specialist palliative care and advice to patients, their families and GPs in association with a local hospice. The relative merits of the specialized hospice versus the non-specialized hospice for the delivery of HIV palliative care have been reviewed previously 18, 19 . Because of speci®c issues in caring for people with HIV, several HIV hospices were establishedÐsuch as the Mildmay Hospital in East London, which when opened in 1987 was Europe's ®rst HIV/AIDS hospice. Staff at such hospices are experienced in the management of HIV-related problems, and as a result are particularly sensitive to the social and psychological issues associated with the disease. In addition, there is the opportunity for patients to meet and gain encouragement from other patients in similar settings. However, since stigma is still very troublesome (even dying patients with HIV may be rejected by family, community or church group), dif®culties can arise if the patient has not been open about the diagnosis to friends and relatives. As the pattern of HIV disease has changed so also has the type of care provided at the Mildmay. In 1987, 90% of patients were male and 50% died in their ®rst admission. In 1999, only 3% of patients died during their ®rst admission and a sizeable number of admissions were for respite care or to the family care centre. There are also dedicated beds for symptom control in patients with brain impairment, and a rehabilitation programme offers help in returning to a reasonable quality of life.
Home (UK)
Patients in the later stages of disease commonly express the desire to die at home, and the extensive experience of community-based physicians, GPs and primary care teams in looking after all patients requiring palliative care can be adapted for people with HIV. However, many patients do not have a GP and are reluctant to register with one. Even if they do register, they may still not disclose their HIV status, because of concerns over con®dentiality and the fear of discrimination 20 . As a result, GPs often become involved with HIV care only at a late stage in the disease course. Hospital support teams and community HIV nurse specialists where available can be helpful, but many patients in our area lack a stable home environment or do not want to access local services, so that dying at home is not a realistic option.
HIV palliative care in the developing world
In less developed countries the picture is very different. Many antiretroviral drugs and other therapies that would prevent disease progression and are part of the continuum of care in developed countries are not available in these resource-poor areas 21 and even the most basic care and symptom control may be unavailable. However, there are a few successful models of palliative care initiatives in these settings. The AIDS Support Organization (TASO) in Uganda was initially founded in 1987 as a self-help support group, but has now developed an outpatient clinic providing basic clinical careÐalthough, with the lack of availability of anti-herpes agents or even¯uconazole or nystatin for candida, and such a high proportion of destitute patients, a bar of soap, a bag of¯our, or some bedding may be the best symptom control on offer. In recognition of the often poorquality care at home that results from stigma, TASO has also begun training and supervision programmes for families and community members in basic home care.
The Mildmay Centre for AIDS palliative care in Kampala, Uganda, which opened to patients in 1998, developed as a joint project between the Ugandan Ministry of Health, the UK Department for International Development and Mildmay International, to provide specialist outpatient palliative care and rehabilitation to HIV-infected patients for a small fee, or free of charge to the destitute. The centre's philosophy of symptom control is disseminated throughout sub-Saharan Africa by a programme of`training the trainers'.
